ADAR1 Capital Management »

Edgewise Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Edgewise Therapeutics (EWTX) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Edgewise Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Edgewise Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Edgewise Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $3.3M 181k 18.24

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Edgewise Therapeutics

OrbiMed Advisors
RA Capital Management
BlackRock
BlackRock
Baker Bros. Advisors
Novo A/S
Vanguard Group
Cormorant Asset Management
Frazier Life Sciences Management
Paradigm Biocapital Advisors
Henderson Group
Perceptive Advisors
TCG Crossover Management
Braidwell
Driehaus Capital Management

View all funds holding Edgewise Therapeutics